Hong Jin

Blue Lake Biotechnology is a startup company that focuses on developing a human vaccine using a novel viral vector. Its goal is to develop PIV5-based vaccines for human disease with an initial focus on the respiratory syncytial virus, as well as obtain the FDA’s approval for a phase I trial.The company is located in Athens, Georgia, and wasfounded in 2019 by Biao He.